6 completed, 2 active not recruiting, 2 recruiting, 1 enrolling by invitation. 13 Phase 1, 8 Phase 2.
Follow Myotonic Disorders: new trials by email Literature Review of Myotonic Disorders trials Research Report on Myotonic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Calcium Channel Blocker in Myotonic Dystrophy Type 1 Amlodipine - Myotonic Dystrophy 1 | Phase 1 | Not yet recruiting | University of Rochester | 20 | 2026-12-07 | 2026-11-09 |
| A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1 SAR446268 - Myotonic Dystrophy | Phase 1 / Phase 2 | Recruiting | Sanofi | 32 | 2025-07-23 | 2026-09-21 |
| Study of ATX-01 in Participants With DM1 ATX-01, Placebo - Myotonic Dystrophy 1 | Phase 1 / Phase 2 | Recruiting | ARTHEx Biotech S.L. | 56 | 2024-10-15 | 2026-02-10 |
| Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy SRP-1003 IV Infusion, Placebo IV Infusion, SRP-1003 SC Injection - Myotonic Dystrophy 1 | Phase 1 / Phase 2 | Enrolling by invitation | Sarepta Therapeutics, Inc. | 78 | 2024-03-04 | 2026-10-05 |
| A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) VX-670, Placebo - Myotonic Dystrophy Type 1 (DM1) | Phase 1 / Phase 2 | Active not recruiting | Vertex Pharmaceuticals Incorporated | 47 | 2024-02-20 | 2026-08-20 |
| Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1 PGN-EDODM1 for infusion, Placebo - Myotonic Dystrophy 1 | Phase 1 | Completed | PepGen Inc | 24 | 2023-12-12 | 2026-02-13 |
| Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 DYNE-101, Placebo - Myotonic Dystrophy Type 1 (DM1) | Phase 1 / Phase 2 | Active not recruiting | Dyne Therapeutics | 127 | 2022-09-05 | 2026-09-23 |
| Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients AOC 1001, Placebo - DM1, Myotonic Dystrophy 1 | Phase 1 / Phase 2 | Completed | Avidity Biosciences, Inc. | 39 | 2021-10-28 | 2026-09-28 |
| Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1 ERX-963, Placebo - Myotonic Dystrophy, Type 1 (DM1), Myotonic Dystrophy | Phase 1 | Completed | Expansion Therapeutics, Inc. | 12 | 2019-06-17 | 2021-06-23 |
| A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 IONIS-DMPKRx, Placebo - Myotonic Dystrophy Type 1 | Phase 1 / Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 48 | 2014-12-01 | 2022-12-06 |
| Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1 Ranolazine - Myotonia Congenita, Paramyotonia Congenita | Phase 1 | Completed | Ohio State University | 35 | 2014-08-01 | 2019-03-05 |
| The Efficacy of Using Far Infrared Radiation to Manage Muscular Dystrophies Far Infrared Radiation - Muscular Dystrophies | Phase 1 | Unknown | GAAD Medical Research Institute Inc. | 4 | 2008-05-01 | 2009-08-17 |
| Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) SomatoKine/IPLEX - Myotonic Dystrophy | Phase 1 / Phase 2 | Completed | University of Rochester | 17 | 2005-11-01 | 2012-06-25 |
Myotonic Dystrophy (13) · Muscular Diseases (3) · Muscular Dystrophies (3) · Neuromuscular Diseases (3) · Genetic Diseases, Inborn (2) · Heredodegenerative Disorders, Nervous System (2) · Muscular Disorders, Atrophic (2) · Musculoskeletal Diseases (2) · Nervous System Diseases (2) · Neurodegenerative Diseases (2) · Disorders of Excessive Somnolence (1) · Distal Myopathies (1) · Glycogen Storage Disease Type V (1) · Muscular Dystrophy, Duchenne (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (13) · Genetic Diseases, Inborn (11) · Heredodegenerative Disorders, Nervous System (11) · Muscular Disorders, Atrophic (11) · Musculoskeletal Diseases (11) · Nervous System Diseases (11) · Neurodegenerative Diseases (11) · Muscular Diseases (10) · Muscular Dystrophies (10) · Neuromuscular Diseases (10) · Carbohydrate Metabolism, Inborn Errors (1) · Dyssomnias (1) · Genetic Diseases, X-Linked (1) · Glycogen Storage Disease (1)
Amlodipine (1) · IGF-I-IGFBP-3 complex (1) · Ranolazine (1) · somatoKine (1)
University of Rochester (2) · ARTHEx Biotech S.L. (1) · Avidity Biosciences, Inc. (1) · Dyne Therapeutics (1) · Expansion Therapeutics, Inc. (1) · GAAD Medical Research Institute Inc. (1) · Ionis Pharmaceuticals, Inc. (1) · Ohio State University (1) · PepGen Inc (1) · Sanofi (1) · Sarepta Therapeutics, Inc. (1) · Vertex Pharmaceuticals Incorporated (1)
United States (10) · Canada (6) · United Kingdom (6) · Australia (4) · France (4) · Italy (4) · Germany (3) · Netherlands (3) · Spain (3) · Belgium (2) · New Zealand (2) · Argentina (1) · Israel (1) · Taiwan (1) · Thailand (1)
Elliot Ehrich, MD (1) · Ken Nedd, M.D. (1) · Li Tai, MD (1) · Richard T. Moxley, III, M.D. (1) · William D Arnold, MD (1)
PMID 20837825, PMID 30390395, PMID 36804094, PMID 40197813, PMID 41707138
2023 (2), U54NS048843 (1)